Telomir Pharmaceuticals (NASDAQ: TELO) announced new in vitro data showing that Telomir-1 (Telomir-Zn) induced broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer, with iron-rescue experiments confirming the effect is iron-dependent and linked to the drug’s proposed intracellular metal-modulating mechanism. The company said supplemental iron significantly attenuated tumor cell mortality, supporting that Telomir-Zn reduces labile redox-active iron while increasing zinc availability, targeting the elevated iron levels and oxidative stress observed in many triple-negative breast cancer tumors.
To view the full press release, visit https://ibn.fm/CHKT9
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The Company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
NOTE TO INVESTORS: The latest news and updates relating to TELO are available in the company’s newsroom at https://ibn.fm/TELO
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN